Avenue Therapeutics, Inc. (ATXI)
Largest Insider Buys in Sector
ATXI Stock Price History Chart
ATXI Stock Performance
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Insider Activity of Avenue Therapeutics, Inc.
Over the last 12 months, insiders at Avenue Therapeutics, Inc. have bought $552,301 and sold $86,560 worth of Avenue Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avenue Therapeutics, Inc. have bought $271,557 and sold $634,165 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ROSENWALD LINDSAY A MD (director) — $1.26M. Fortress Biotech, Inc. (10 percent owner) — $301,255.
The last purchase of 418,410 shares for transaction amount of $301,255 was made by Fortress Biotech, Inc. (10 percent owner) on 2023‑09‑08.
List of Insider Buy and Sell Transactions, Avenue Therapeutics, Inc.
| 2023-12-11 | Sale | Davidow Robert L | 10 percent owner | 617,000 4.9094% | $0.14 | $86,560 | +5.88% | |
| 2023-09-08 | Fortress Biotech, Inc. | 10 percent owner | 418,410 4.9086% | $0.72 | $301,255 | -79.79% | ||
| 2023-09-08 | ROSENWALD LINDSAY A MD | director | 348,675 4.0905% | $0.72 | $251,046 | -79.79% | ||
| 2022-10-11 | Sale | InvaGen Pharmaceuticals, Inc. | director | 388,888 48.3396% | $7.71 | $3M | -59.86% | |
| 2021-09-15 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 7,160 0.042% | $1.62 | $11,599 | -69.16% | |
| 2021-05-06 | Herskowitz Neil | director | 2,500 0.0142% | $3.99 | $9,975 | -68.56% | ||
| 2020-08-20 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 3,840 0.0235% | $12.13 | $46,579 | -60.88% | |
| 2020-03-10 | Vazzano Joseph Walter | Chief Financial Officer | 1,889 0.0115% | $7.94 | $14,999 | +12.63% | ||
| 2020-03-09 | Vazzano Joseph Walter | Chief Financial Officer | 1,500 0.0093% | $7.99 | $11,983 | +13.49% | ||
| 2020-02-27 | Herskowitz Neil | director | 2,400 0.0139% | $8.20 | $19,680 | +3.72% | ||
| 2020-02-26 | Herskowitz Neil | director | 161 0.001% | $8.73 | $1,406 | +0.45% | ||
| 2020-02-25 | Herskowitz Neil | director | 10,000 0.0629% | $9.31 | $93,100 | -0.89% | ||
| 2020-02-25 | Vazzano Joseph Walter | Chief Financial Officer | 1,200 0.0074% | $9.09 | $10,908 | -0.89% | ||
| 2019-09-12 | Ingram Elizabeth Garrett | director | 16,000 0.0982% | $6.27 | $100,320 | +46.39% | ||
| 2019-08-09 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 2,375 0.0138% | $5.56 | $13,205 | +49.32% | |
| 2019-08-08 | Sale | Vazzano Joseph Walter | Chief Financial Officer | 2,313 0.0141% | $5.62 | $12,999 | +55.35% | |
| 2019-06-18 | Herskowitz Neil | director | 2,000 0.0126% | $5.83 | $11,660 | +21.09% | ||
| 2019-06-17 | Herskowitz Neil | director | 3,000 0.0182% | $5.88 | $17,640 | +15.92% | ||
| 2019-04-15 | Herskowitz Neil | director | 1,000 0.0061% | $4.52 | $4,520 | +33.63% | ||
| 2019-03-29 | Herskowitz Neil | director | 1,400 0.011% | $5.11 | $7,154 | +26.95% |
Institutional Investor Ownership
No records found… | |||||||